목차
Title page 1
Contents 1
What's the issue? 2
Why is this important? 2
What can be done about it? Agile governance and financial mixes 5
References 9
Tables 3
Table 1. Financing and market creation instruments for biosolutions in the European Union and the United States 3
Table 2. Biotechnology regulatory barriers across the E.U. and U.S. 4
Figures 2
Figure 1. Patent applications in the biotechnology sector by jurisdiction and OECD member countries 2
Figure 2. Financing for biotechnology innovations for startups and greenfield facilities across the European Union and the United States, 2013-2022 4
Figure 3. Distribution of selected agile mechanisms across the policy cycle 5
Boxes 7
Box 1. United Kingdom Engineering Biology Sandbox Fund 7
